Pulmonary Fibrosis
Pulmonary Fibrosis - Related Videos
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
0 Views •
2025
This protocol delineates a method for inducing pulmonary fibrosis in mice through repeated oropharyngeal administration of bleomycin, yielding pathological features closely resembling those of idiopathic pulmonary fibrosis.
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
0 Views •
2026
Here, we present a protocol to model pulmonary fibrosis in mice using aerosolized bleomycin delivered via the trachea. This optimized method enables uniform, quantitative, and precise delivery without surgical incision, enhancing the reproducibility and reliability of bleomycin-induced fibrosis.
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
0 Views •
Cited by 2 •
2025
This protocol demonstrates the oropharyngeal aspiration technique for use in the bleomycin murine model of pulmonary fibrosis.
07:11
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
0 Views •
2025
Here, the method of inducing pulmonary arterial hypertension associated with pulmonary fibrosis (PF-PH) rat model by injecting bleomycin into the airway is introduced. We also provide a step-by-step approach to validate this animal model.
02:46
A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
0 Views •
Cited by 4 •
2023
Various animal models of pulmonary fibrosis have been established using bleomycin to clarify the pathogenesis of pulmonary fibrosis and find new drug targets. However, most pulmonary fibrosis models targeting lung tissue have uneven drug administration. Here, we propose a model of uniform pulmonary fibrosis induced by nasal bleomycin nebulization.
FAQs
Repeated alveolar injury can push lung repair toward persistent scarring when repair becomes abnormal. This response activates inflammatory signaling and fibroblasts, linking the initial tissue damage to later structural remodeling. The biological importance of this sequence is that it explains how an ongoing or misdirected repair response can progressively alter lung tissue rather than restore its original condition.
Fibroblasts contribute to progression by depositing excessive extracellular matrix proteins, including collagen, within lung tissue. This accumulation changes the structure of the interstitium and supports the development of scar tissue. Studying fibroblast activity therefore helps researchers connect cellular behavior with tissue-level remodeling and identify processes that antifibrotic treatments may need to influence.
Reduced lung compliance makes the lungs stiffer, limiting their ability to expand normally. As scarring thickens the interstitium, the distance and structural barrier involved in oxygen transfer are altered, disrupting gas exchange. This relationship connects microscopic extracellular matrix accumulation with a major functional outcome and explains why progressive remodeling can reduce lung performance.
Abnormal repair can maintain inflammatory signaling and fibroblast activation after alveolar injury, allowing extracellular matrix deposition to continue. Instead of resolving the damage, this response promotes progressive remodeling and increasing stiffness. The distinction matters biologically because it identifies faulty repair, rather than injury alone, as a process that can drive lasting loss of lung function.
Research examines pulmonary fibrosis across several biological levels, from cellular responses to injury and fibroblast activity to extracellular matrix deposition and altered lung function. This integrated approach connects tissue remodeling with disease progression. It also provides a framework for improving diagnosis, evaluating antifibrotic treatments, and investigating strategies intended to preserve or restore lung function.
Antifibrotic treatment research evaluates whether an intervention can limit the processes associated with progressive scarring and support preservation of lung function. The relevant biological context includes inflammatory signaling, fibroblast activity, and excessive extracellular matrix deposition. Connecting treatment evaluation to these mechanisms helps researchers assess therapies in relation to both tissue remodeling and functional outcomes.
Regenerative strategies are investigated because pulmonary fibrosis can involve persistent structural remodeling and impaired lung function. Research in this area asks whether damaged or remodeled lung tissue can be preserved or restored rather than only studied after scarring has progressed. This work links cellular repair mechanisms with the broader goal of maintaining effective oxygen transfer and lung performance.